Oncology survey finds optimism, cost concerns

March 2010
Clinical Trials Administrator;Mar2010, Vol. 8 Issue 3, p33
The article discusses a survey sponsored by the U.S. Oncology which revealed that optimism was found for personalized medicine in clinical trials. The KJT Group conducted interviews of 299 oncologists, hematologists and clinical trial practitioners. Findings of the survey indicated that 57.5% of respondents are optimistic about U.S. clinical trials in the future while 17.1% are pessimistic and 21.1% are ambivalent. Among the respondents, 44% said that the lack of funding slow down the process while 29% considered the excessive analysis.


Related Articles

  • Geriatric Oncology Aims For Clinical Trials. Sinha, Gunjan // JNCI: Journal of the National Cancer Institute;11/1/2006, Vol. 98 Issue 21, p1516 

    The article reports on the plans of geriatric oncology for clinical trials. The section offers several reports in connection with the study, including common problems of older people. The section also presents guidelines for scientists given by Martine Extermann to boost participation of the...

  • Clinical Trial Results Applied to Management of the Individual Cancer Patient. Jatoi, Ismail; Proschan, Michael A. // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1184 

    The application of clinical trial results to the management of the individual cancer patient is not always straightforward. The results of a clinical trial indicate the “average” effect of an intervention, often expressed in terms of an absolute risk reduction, which is an estimate...

  • Clinical Trials in Surgical Oncology–Introduction. Jatoi, Ismail // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1137 

    The article reports on the importance of clinical trials in managing cancer and cancer patients. Clinical trials as well as patient participation in trials conducted, has contributed in stabilizing mortality rates of cancer patients and has brought improvement in managing the disease....

  • Oncology Trial Comparator Drug Reimbursement: A Canadian Perspective. Deakin, Denise // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p32 

    The article examines the Canadian comparator reimbursement climate to better inform trial expansion decisions. The author talks about the importance of comparators in cancer trials in the country. Also tackled is the potential for Canada to be a prospective region for the expansion of both early...

  • Clinical Medicine and Clinical Trials. Tepper, Joel E. // Oncologist;Apr2010, Vol. 15 Issue 4, p382 

    The article presents the author's insights on issues related to clinical oncology particularly on radiation oncology. The author states that good clinical trials are necessary for clinicians to know when and how to apply diagnostic and therapeutic procedures. It also discusses the relationship...

  • PER-PATIENT COSTS CLIMB THROUGH CLINICAL TRIAL.  // Biotech Business;May2013, Vol. 26 Issue 5, p6 

    The article discusses a study on the correlation between patient enrollment and total cost as depicted in the Cutting Edge Information study. It provides an overview of the study involving the phase 1, 2 and 3 of the clinical trials and its average total cost. It also highlights the latest...

  • Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial. Panici, Pierluigi Benedetti; Maggioni, Angelo; Hacker, Neville; Landoni, Fabio; Ackermann, Sven; Campagnutta, Elio; Tamussino, Karl; Winter, Raimund; Pellegrino, Antonio; Greggi, Stefano; Angioli, Roberto; Manci, Natalina; Scambia, Giovanni; Dell'Anna, Tiziana; Fossati, Roldano; Floriani, Irene; Rossi, Rita S.; Grassi, Roberto; Favalli, Giuseppe; Raspagliesi, Francesco // JNCI: Journal of the National Cancer Institute;4/20/2005, Vol. 97 Issue 8, p560 

    Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy...

  • The New Road of Cardio-Oncology in Clinical Development. Herron, David S. // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p38 

    The article discusses the developments in cardoi-oncology in clinical development. The author provides an overview about the clinical discipline, cardio-oncology, which aims to bridge the gap between cardiology and oncology and promote safer drugs and better outcomes for cancer patients. Also...

  • Clinical Trials: What You and Your Patients Need to Know. Yoder, Linda H. // MEDSURG Nursing;Oct2005, Vol. 14 Issue 5, p351 

    The article presents information on the clinical trials designed for oncology. Oncology clinical trials are prospectively designed research evaluations of new interventions for the prevention, diagnosis, treatment, and improvement of quality of life of people diagnosed with cancer. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics